PDGFRA and bladder transitional cell carcinoma: Nearly 4% of patients harbored mutations in PDGFRA and MET each and 3% in ZFB1, COL3A1, and COL1A2. Next, we determined CNV in CRGs, and the results revealed the highest number of CNV gains in CTSK, S100A4, and CTHRC1 in patients with BLCA (Figure 1B).